Continued treatment with TG Therapeutics’ Briumvi (ublituximab) provides sustained clinical benefits for people with relapsing forms of multiple sclerosis (MS), particularly if started earlier. That’s according to data from the ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) Phase 3 clinical trials and their ongoing open-label extension (NCT04130997). After five years of follow-up, more than 80%…
Intention & Expectations
By Stacie Prada Lately, I’ve been pausing periodically throughout each day to ask myself, “How do I want to show up today?” It only takes a moment, just enough time for a brief inhale and exhale. It allows me to … Continue reading → Source: blog.mymsaa.org
It may not always look like it, but I’m not giving up
Several (OK, many) years ago, I was having lunch with a group of fellow Green Berets when a news story appeared on the TV. The report covered a recent tragedy, and during an interview with a survivor, it was mentioned that one of the victims had not survived because they had “given up.” This sparked…
UCSF, Nektar team to test potential of antibody therapy for MS
The University of California San Francisco (UCSF) is teaming up with Nektar Therapeutics to study the potential of NKTR-0165, an experimental antibody that activates the tumor necrosis factor receptor type 2 (TNFR2), to treat multiple sclerosis (MS). UCSF neurologist Stephen L. Hauser, MD, and his postdoctoral researcher Chaitrali Saha, PhD, will lead the project. The…
Breastfeeding as a baby could slow MS progression later in life
Breastfeeding for longer during infancy may delay the onset of multiple sclerosis (MS) and slow its progression for people who later develop the disease, according to a study from Turkey. Researchers found that adults with MS who had been breastfed for more than six months had less severe disease than those who had been breastfed…
Cost of Drugs
Tweet Hartung DM et al. Changes in List and Net Prices for Multiple Sclerosis Disease-Modifying Therapy, 2013 to 202116 e200597 Neurol Clin Practise 2026 https://doi.org/10.1212/CPJ.00000000002005 This is a paper that tweaked my interest and says to the people in the UK to spare a thought for those in the US and their drug costs. No wonder…
Pharma funds to Neuros and others..No wonder they cost so much
Tweet You wanted it you got it the hottest band in the World….Piss I meant you wanted it you got…..Neurologists feeding from the Pharma trough. You may have noted that the costs of MS drugs in the USA, are particularly high. Well if you want your want to know where your money is going? Some…
Subtle voice changes may help doctors identify multiple sclerosis faster
Canary Speech and Intermountain Ventures are collaborating to test whether subtle changes in a person’s voice can help identify multiple sclerosis (MS), potentially paving the way for noninvasive tools to diagnose the disease faster. The research will rely on Canary’s vocal biomarker technology and be led by Timothy West, MD, a neurologist at Intermountain Health’s Salt…
Funding to support Immunic Phase 3 MS trials, commercialization
Immunic Therapeutics has closed a private placement that could provide up to $400 million to support the company’s Phase 3 clinical program of vidofludimus calcium in multiple sclerosis (MS) and help fund its transition into a commercial-stage company as it prepares for potential regulatory approval of the oral therapy. The financing will support completion of…
Self-Connection
By Angel Blair When we hear the word relationships we often think about the connections we have to others. Bonds with our family, friends, significant others, etc. So we tend to forget one of the most important but commonly overlooked relationships … Continue reading → Source: blog.mymsaa.org